Ractigen Therapeutics is a pioneering early-stage pharmaceutical company dedicated to developing revolutionary therapies. Their focus lies in creating first-in-class treatments that boost the expression of therapeutic genes within diseased cells. They achieve this through the utilization of saRNA, a short duplex RNA known as small activating RNA, which selectively turns genes on.

This groundbreaking RNAa technology stimulates the production of targeted genes, making Ractigen Therapeutics one of the few companies with the ability to activate endogenous genes. Their diverse pipeline spans a range of previously untreatable diseases and monogenic disorders, including oncology, CNS, and liver-related indications. By exploring the boundaries of their technology, Ractigen Therapeutics is aiming to propel the next generation of RNAa therapeutics.

Leading this innovative company is a cohesive team of scientific and professional experts, including the inventors of RNAa technology, nucleic acid chemists, biotech entrepreneurs, and drug discovery specialists. Ractigen Therapeutics has garnered recognition and funding for their groundbreaking research, with notable achievements such as closing a $30 million Series A+ funding round and being named one of the top RNA biotech companies in China. They are continuously seeking passionate individuals at all career levels to join their team and contribute to the breakthrough drug class of the future.

Contact Ractigen Therapeutics today to unleash the power of RNAa and combat disease